Focused Ultrasound Reprogrammed Microglia in Alzheimer’s Rats

TL;DR: A 2026 bioRxiv preprint found repeated low-intensity focused ultrasound in Alzheimer’s rats changed blood-brain-barrier and microglial biology but did not clearly improve Alzheimer’s pathology on its own.

Source: bioRxiv (2026) | Abjean et al.

Focused Ultrasound Temporarily Opened the Blood-Brain Barrier (BBB)

Alzheimer’s drug development has a geometry problem. Antibodies like lecanemab and donanemab can bind amyloid, but the blood-brain barrier makes it hard to get enough drug into the brain without giving large systemic doses that raise side-effect risk.

Low-intensity focused ultrasound with intravenous microbubbles can temporarily loosen the barrier, letting researchers deliver more treatment to the brain with less drug in the bloodstream.

But barrier opening is not biologically neutral. It physically perturbs vessels, glia, and the inflammatory environment. The study is important because it asked what that perturbation does in an Alzheimer’s model even before the technology is paired with a therapeutic payload.

One Session Helped a Specific Amyloid Pool

The initial surprise came from the single-treatment arm in 18–19-month-old TgF344-AD rats.

Within 24 hours, the procedure nudged inflammatory genes upward (Aif1, Gfap, Vimentin, Tspo, Il6, Rantes) but tissue-level IBA1 and GFAP stains did not move enough to show an obvious morphologic response.

Pathology readouts were mixed. The earliest effect was selective, fast, and probably tied to how different amyloid pools respond to barrier opening — not a general reset of Alzheimer’s pathology.

• Aβ42: the highly aggregated guanidine-soluble fraction fell after one exposure.
• Aβ40: the same single-session effect did not appear.
• pTau231: tau pathology stayed flat after the single exposure.

Safety was nuanced. Microhemorrhages were visible at 24 hours, which is not trivial in an amyloid-laden brain, but they had resolved by day 7 and did not obviously stack with weekly treatment. Reassuring for the technology, though it still means the procedure creates a real acute vascular insult that cannot be waved away as harmless.

Repeated Ultrasound Reduced TSPO Signal Without Clearing Plaques

Adding more ultrasound was not simply better ultrasound. Four weekly LiFUS sessions in older rats produced a persistent inflammatory transcriptional signature 7 days after the last treatment — heavily microglial.

That was the time point where pathology markers looked least encouraging. Aggregated Aβ42 rose instead of fell.

pTau231 rose. Exactly the wrong directions if you were hoping repeated barrier opening alone would steadily chip away at Alzheimer’s hallmarks.

The pattern changed again 6 weeks later. The short-term inflammatory signature had largely faded, Aβ42 and pTau231 were no longer different, and only guanidine-soluble Aβ40 remained lower.

The pattern is less a clean therapeutic arc than a rebound sequence: short-term disturbance, partial normalization, no convincing sign that ultrasound by itself meaningfully changed the disease trajectory in aged animals.

Younger Rats Showed Reprogramming, Not Plaque Clearance

The early-stage cohort is the most important part of the study. When researchers started the same four-session protocol in younger, pre-symptomatic rats, the treatment still did not clearly reduce amyloid or tau. But it changed microglial biology in a way more consistent with reprogramming than acute activation.

TSPO dropped in both total parenchyma and sorted microglia. P2y12r fell.

Tnfα rose. Tgfβ trended upward. That is not a neat pro-inflammatory or anti-inflammatory interpretation — the researchers explicitly argue for a continuum model where microglia adapt to the changed vascular and metabolic environment.

Metabolic hints came too. Glut1 increased, Mct1 trended down, Vdac1 also trended lower — a pattern the authors interpret as a shift toward glycolytic metabolism. Repeated barrier opening may be nudging microglia away from one energy strategy and toward another, especially when the procedure is started early in disease.

TSPO Timing Separated Acute Inflammation From Later Microglial Adaptation

That metabolic angle keeps this paper from collapsing into a simple “ultrasound caused inflammation” story. TSPO is often treated as a marker of neuroinflammation, but here it moved in opposite directions depending on timing. It increased after acute exposure, then fell weeks later after repeated treatment, especially in younger animals.

The researchers argue that split makes biological sense. The early TSPO rise is consistent with a transient inflammatory response to barrier opening. The later TSPO reduction, paired with shifts in Tnfα, Glut1, and mitochondrial genes, is more consistent with a sustained functional adaptation in microglia.

If focused ultrasound is eventually used as a drug-delivery platform, its value may depend not just on how much barrier it opens, but on whether repeated exposures are quietly reshaping the immune-metabolic state of the brain around the therapy.

Focused Ultrasound Worked Better as a Delivery Tool Than a Standalone Therapy

The final result is more restrained than the field’s hype. In these rats, repeated LiFUS plus microbubbles did not reliably improve core Alzheimer’s pathology markers on its own. It produced some potentially useful biological effects, but they were conditional on disease stage and time point — and several of the short-term changes moved the wrong direction.

That does not make the approach a failure. It clarifies where the technology is strongest.

Focused ultrasound still looks promising as a drug-delivery tool that could reduce systemic dose for antibodies or other therapeutics. What this study does not support is the stronger claim that repeated barrier opening by itself is already an Alzheimer’s treatment.

The important biology here is not plaque removal — it is that microglia may be one of the main long-term responders to repeated ultrasound-mediated barrier opening, especially early in disease, and any future therapeutic strategy will need to account for that biology rather than treating the ultrasound step as passive plumbing.